ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL

ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL

The treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a major clinical challenge. While CAR-T cell therapy can induce rapid and deep remissions, many patients continue to face a substantial risk of relapse. Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy has emerged as a promising curative strategy. However, evidence regarding its long-term efficacy, optimal timing, and the role of molecular biomarkers in guiding treatment decisions has remained limited.
CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

The 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting were held in Beijing from June 9–13, 2026. On June 10, the dedicated ASCO Neuroendocrine Tumors Highlights Session brought together leading Chinese experts to provide in-depth reviews of the latest advances in neuroendocrine tumor (NET) research presented at the 2026 ASCO Annual Meeting.
CGOG 2026 Day 3 | ASCO Highlights Session on Colorectal Cancer

CGOG 2026 Day 3 | ASCO Highlights Session on Colorectal Cancer

On June 11, Day 3 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting featured the 2026 ASCO Highlights Session on Colorectal Cancer, where leading experts provided in-depth reviews and discussions of the latest advances presented at the 2026 ASCO Annual Meeting. The session was livestreamed across multiple platforms and attracted more than 25,000 online viewers.
Exclusive Interview with Prof. Weiren Huang: Reflecting on the Discipline’s Legacy and the Next Decade of Tumor Organoids | The 2nd Peking University Urology Forum

Exclusive Interview with Prof. Weiren Huang: Reflecting on the Discipline’s Legacy and the Next Decade of Tumor Organoids | The 2nd Peking University Urology Forum

During the 2nd Peking University Urology Forum and the celebration of the 80th anniversary of the Department of Urology at Peking University First Hospital, Oncology Frontier – UroStream interviewed Prof. Weiren Huang from the Department of Urology, First Affiliated Hospital of Shenzhen University (Shenzhen Second People’s Hospital).
ASCO Highlights | Professor Yijun Shen: Dual Frontiers in Urologic Oncology Move Earlier as Chinese-Developed Immunotherapy Combinations Continue to Shine

ASCO Highlights | Professor Yijun Shen: Dual Frontiers in Urologic Oncology Move Earlier as Chinese-Developed Immunotherapy Combinations Continue to Shine

Chinese-developed immune checkpoint inhibitors, represented by toripalimab, are accelerating the transition of innovative therapies in urologic oncology from followers to global contributors. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Chinese innovation was not only featured in oral presentations but also prominently showcased in the poster halls. Toripalimab combined with 9MW2821 demonstrated promising bladder-preservation potential after moving from advanced disease into the perioperative setting. Immunotherapy plus chemotherapy expanded a uniquely Chinese approach to bladder preservation. Meanwhile, a phase III neoadjuvant trial of toripalimab combined with axitinib in renal cell carcinoma marked the first randomized evaluation of a targeted-immunotherapy combination moving from the frontline setting into neoadjuvant treatment. In this issue, Oncology Frontier invited Professor Yijun Shen from Fudan University Shanghai Cancer Center to discuss key poster presentations and share his perspectives on the evolving landscape of immunotherapy in urologic oncology at this year's ASCO meeting.
ASCO Spotlight | Prof. Jun Guo & Prof. Shilpa Gupta: 3.5-Year EV-302 Follow-Up Highlights the Curative Potential of EV + Pembrolizumab in Advanced Urothelial Carcinoma

ASCO Spotlight | Prof. Jun Guo & Prof. Shilpa Gupta: 3.5-Year EV-302 Follow-Up Highlights the Curative Potential of EV + Pembrolizumab in Advanced Urothelial Carcinoma

The 2026 ASCO Annual Meeting has officially opened, bringing a wealth of landmark studies in genitourinary oncology and providing new momentum for precision treatment in urothelial carcinoma (UC). To promote standardized and precision-based management of urologic cancers in China, the Hainan Lecheng Hongyuan Medical Technology Innovation and Development Research Institute launched the “Academic Exchange Program on Precision Diagnosis and Treatment of Urologic Tumors,” bringing together leading experts to interpret the latest advances.